Urolithin A for ALS
Also known as: UA, Mitopure
Urolithin A induces mitophagy — selective clearance of damaged mitochondria — addressing mitochondrial quality control failure in ALS.
Mechanism of Action
Urolithin A activates PINK1/Parkin-dependent mitophagy, clearing dysfunctional mitochondria and promoting replacement with healthy ones. It also activates AMPK and inhibits mTORC1, creating a cellular environment favoring mitochondrial quality control.
General mechanism: Gut microbiome metabolite from ellagitannins. PINK1/Parkin mitophagy activator, AMPK activator, mTORC1 inhibitor.
Current Evidence
Preclinical evidence for neuroprotection through mitophagy. Human trials show improved mitochondrial biomarkers. No ALS-specific studies.
Clinical Status: Phase II for muscle aging. No ALS trials. Available as supplement (Mitopure).
Safety Profile
Very safe. Naturally derived from pomegranate/ellagitannin metabolism. Well-tolerated in clinical trials.
Key Research Questions
- Can UA-induced mitophagy rescue motor neurons with mitochondrial dysfunction?
- Does UA reach motor neurons at sufficient concentrations?